First AD

Second AD

Bladder Cancer

Around the Practice

Previously recorded peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on case presentations and audience engagement on important issues facing today's cancer care professionals.

Genitourinary Cancers

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.  

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Recent Treatment Advances in Urothelial Cancer

Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

The Role of Biomarkers in Immunotherapy Selection for mUC

JAVELIN Bladder 101: Study Design and Patient Outcomes

Strategies and Barriers in mUC Maintenance Therapy

Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Maintenance Therapy Duration and Considerations for Treatment Interruption

Treatment Options After Progression on Frontline Maintenance Therapy

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

ASCO GU 2022 Updates: Antibody-Drug Conjugates